Newswire (Published: Wednesday, April 22, 2020, Received: Wednesday, April 22, 2020, 6:03:06 PM CDT)

Word Count: 477

2020 APR 22 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Current study results on Oncology - Prostate Cancer have been published. According to news originating from Orange, California, by NewsRx correspondents, research stated, “To evaluate risk of prostate cancer biochemical recurrence (BCR) after radical prostatectomy (RP) in men receiving vs not receiving testosterone replacement therapy (TRT). A total of 850 patients underwent RP by a single surgeon.”

Our news journalists obtained a quote from the research from the University of California Irvine, “All patients had preoperative testosterone and sex hormone-binding globulin levels determined; free testosterone was calculated prospectively. In all, 152 (18%) patients with low preoperative calculated free testosterone (cFT) levels and delayed postoperative sexual function recovery were placed on TRT and proportionately matched to 419 control patients by pathological Gleason Grade Group (GGG) and stage. Rates and time to BCR [two consecutive prostate-specific antigen (PSA) levels of >= 0.2 ng/mL] were compared in univariate and multivariate regression; Cox regression was used to generate a survival function at the mean of covariates. The median follow-up was 3.5 years. There were no statistically significant differences in demographics or general health complications between groups. BCR occurred in 11/152 (7.2%) and 53/419 (12.6%) patients in the TRT and control groups, respectively. In adjusted time-to-event analysis, TRT was an independent predictor of recurrence-free survival. After accounting for GGG, pathological stage, preoperative PSA level, and cFT, patients on TRT were similar to 54% less likely to recur (hazard ratio 0.54, 95% confidence interval 0.292-0.997). In men destined to recur, TRT delayed time to recurrence by an average of 1.5 years. In our experience, TRT after RP significantly reduced BCR and delayed time to BCR. There was no identifiable general health complications associated with TRT.”

According to the news editors, the research concluded: “These findings are hypothesis-generating and require confirmation with multi-centred, prospective randomised controlled trials.”

For more information on this research see: Testosterone replacement therapy reduces biochemical recurrence post-radical prostatectomy. BJU International, 2020;():. BJU International can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell -; BJU International -

The news correspondents report that additional information may be obtained from T.E. Ahlering, University of California Irvine, Irvine Med Ctr Orange, Dept. of Urology, Orange, CA 92668, United States. Additional authors for this research include L.M. Huynh, M. Towe, K. See, J. Tran, K. Osann, F.M. el Khatib and F.A. Yafi.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)


University of California Irvine


North America
United States
Orange County


Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices
      Treatments and Therapies